BEKE(02423)
Search documents
贝壳-W8月14日斥资400万美元回购64.98万股

Zhi Tong Cai Jing· 2025-08-15 11:30
贝壳-W(02423)发布公告,于2025年8月14日斥资400万美元回购64.98万股。 ...
贝壳-W(02423.HK)8月14日耗资400万美元回购65万股

Ge Long Hui· 2025-08-15 11:21
Group 1 - The company, Beike-W (02423.HK), announced a share buyback plan, intending to repurchase 650,000 shares at a cost of $4 million [1]
贝壳(02423) - 翌日披露报表

2025-08-15 11:15
FF305 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 不同投票權架構公司普通股 | 股份類別 A | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02423 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份(不包括庫存股份)變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份(不包括庫存股份)數 目 | 佔有關事件前的現有已發 行股份(不包括庫存股 份)數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2025年8月13日 | 3,430,132,293 | | 0 | | 3,430,132,293 | | 1). 其他 (請註明) | | | % | | | | | 見B部分 | | | | | | | | 變動日期 2025年8月14日 | | | | | | | | 於下列日期結束時的結存 (註5及6 ...
桥水清仓阿里、京东等中概股
3 6 Ke· 2025-08-15 01:59
Core Viewpoint - Bridgewater Associates significantly increased its holdings in major US tech stocks, including Nvidia, Microsoft, Google, and Meta, while completely divesting from several Chinese stocks like Alibaba, Baidu, and JD.com [1][5]. Group 1: Holdings Changes - As of the end of Q2, Bridgewater's portfolio value rose from $21.6 billion to $24.8 billion, with 85 new positions, 206 increased positions, 164 closed positions, and 187 reduced positions [2]. - The top ten holdings at the end of Q2 included SPDR S&P 500 ETF (SPY), iShares Core S&P ETF (IVV), Nvidia, iShares Core MSCI Emerging Markets ETF (IEMG), Google A, Microsoft, Meta, Salesforce, Booking Holdings Inc (BKNG), and GE Vernova Inc (GEV) [2]. Group 2: Major Increases in Tech Stocks - Nvidia was the most significantly increased stock, with Bridgewater adding nearly 4.39 million shares, bringing total holdings to 7.23 million shares, a 154% increase from the previous quarter, making it the third-largest holding at 4.61% of the portfolio [4]. - Microsoft, Google A, and Meta also saw substantial increases, indicating Bridgewater's optimistic outlook on these AI giants [4]. Group 3: Reductions in Other Stocks - Amazon experienced a reduction of approximately 795,500 shares, a decrease of about 6%, dropping its portfolio share from 1.17% to 1.10% [4]. - Apple shares were reduced by 584,000, a 62% decrease, lowering its portfolio share from 0.97% to 0.30% [4]. - AMD also saw a reduction of 408,900 shares, a decline of nearly 18.9%, making it the 21st largest holding [4]. Group 4: Divestment from Chinese Stocks - Bridgewater completely divested from Alibaba, selling all 5.66 million shares, as well as 2.79 million shares of JD.com and 2.08 million shares of Baidu [5]. - This marks a significant reversal from Q1, where Bridgewater had increased its holdings in Alibaba and Baidu [5].
高瓴HHLR二季度美股持仓:31亿美元九成押注中概股,拼多多稳居第一
Jin Rong Jie· 2025-08-14 22:39
Core Insights - HHLR Advisors, a fund management platform under Hillhouse Capital, reported a total market value of $3.105 billion in its U.S. stock holdings as of the end of Q2 2025, with over 90% allocated to Chinese concept stocks, indicating a long-term bullish outlook on quality Chinese assets [1] Group 1: Holdings Overview - Eight out of the top ten holdings of HHLR are Chinese concept stocks, with Pinduoduo being the largest position, having increased by 20% year-to-date [1] - Futu Holdings has seen a remarkable year-to-date increase of 106%, reflecting strong performance among HHLR's key investments [1] - Other notable holdings include BeiGene, NetEase, Alibaba, and Legend Biotech, all of which have shown significant performance [1] Group 2: Recent Changes in Holdings - In Q2, HHLR increased its positions in Futu Holdings and Pinduoduo while partially reducing its stakes in Alibaba, Beike, and NetEase, which have experienced substantial price increases of 52% and 54% respectively year-to-date [1] - This adjustment in holdings suggests a strategy focused on locking in profits and optimizing asset allocation in a high market environment [1] Group 3: New Entrants - For the first time, Moomoo Securities entered HHLR's top ten holdings, with Hillhouse having participated in multiple financing rounds since 2021; Moomoo went public on NASDAQ in April this year, currently valued at approximately $7.5 billion [1]
格隆汇公告精选(港股)︱荣昌生物(09995.HK):泰它西普(商品名:泰爱®)治疗原发性乾燥综合征中国III期临床研究达到主要终点
Ge Long Hui· 2025-08-14 14:59
Group 1: Core Insights - Rongchang Biologics (09995.HK) announced that its innovative drug Taitasip (brand name: Tai Ai®) for treating primary Sjögren's syndrome has met the primary endpoint in a Phase III clinical trial in China [1] - Taitasip is the first BLyS/APRIL dual-target fusion protein drug to complete Phase III research in the field of Sjögren's syndrome globally [1] - The clinical trial was a multi-center, randomized, double-blind, placebo-controlled study aimed at evaluating the efficacy and safety of Taitasip, with the primary endpoint being the change in ESSDAI score at week 24 compared to baseline [1] Group 2: Disease Background and Drug Mechanism - Sjögren's syndrome is a chronic inflammatory autoimmune disease characterized by lymphocytic infiltration and damage to exocrine glands, leading to persistent dry mouth and dry eyes, and can affect multiple organ systems [2] - The prevalence of Sjögren's syndrome in China is estimated to be between 0.3% and 0.7%, with an increasing trend indicating a significant unmet clinical need [2] - Taitasip is a novel dual-target fusion protein developed by the company that simultaneously inhibits the overexpression of BLyS and APRIL, effectively preventing abnormal differentiation and maturation of B cells [2] Group 3: Regulatory and Clinical Recognition - Taitasip has received multiple authoritative guideline recommendations in China, including the "Clinical Practice Guidelines for Sjögren's Syndrome" and the "Expert Consensus on B-cell Targeted Therapy for Rheumatic and Immune Diseases" [2] - Internationally, Taitasip has been granted Fast Track designation by the U.S. FDA for its indication in Sjögren's syndrome and has been approved to conduct global multi-center Phase III clinical trials [2]
中证港股通地产指数报1690.69点,前十大权重包含中国海外发展等
Jin Rong Jie· 2025-08-14 11:59
Core Viewpoint - The China Securities Index for Hong Kong Real Estate has shown significant growth, with a 3.85% increase over the past month, 11.21% over the past three months, and 18.11% year-to-date [1]. Group 1: Index Performance - The China Securities Index for Hong Kong Real Estate is currently at 1690.69 points [1]. - The index is based on a sample of up to 50 eligible Hong Kong-listed companies that reflect the real estate theme, with a base date of November 14, 2014, set at 3000.0 points [1]. Group 2: Index Holdings - The top ten weighted companies in the index are: - Sun Hung Kai Properties (14.13%) - Beike-W (12.29%) - China Resources Land (11.61%) - Cheung Kong Property (8.01%) - China Overseas Land & Investment (6.29%) - Wharf Real Estate Investment (4.49%) - Sino Land (4.44%) - Henderson Land Development (4.22%) - Longfor Group (2.96%) - China Resources Mixc Lifestyle (2.74%) [1]. Group 3: Market and Industry Composition - The index's holdings are entirely composed of the real estate sector, with 100% representation from the Hong Kong Stock Exchange [2][3]. - The index samples are adjusted biannually, with adjustments occurring on the second Friday of June and December [3].
贝壳-W8月13日斥资约400万美元回购65.26万股

Zhi Tong Cai Jing· 2025-08-14 10:42
贝壳-W(02423)发布公告,于2025年8月13日该公司斥资约400万美元回购65.26万股,回购价格为每股 6.09-6.19美元。 ...
贝壳-W(02423.HK)8月13日耗资400万美元回购65.26万股

Ge Long Hui· 2025-08-14 10:39
格隆汇8月14日丨贝壳-W(02423.HK)发布公告,2025年8月13日耗资400万美元回购65.26万股。 贝壳-W(02423.HK)8月13日耗资400万美元回购65.26万股 贝壳-W(02423.HK)拟8月26日举行董事会会议 批准中期业绩 相关事件 ...
贝壳(02423) - 翌日披露报表

2025-08-14 10:26
FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司(「香港聯交所」)證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露,必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 不同投票權架構公司普通股 | 股份類別 A | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02423 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份(不包括庫存股份)變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份(不包括庫存股份)數 目 | 佔有關事件前的現有已發 行股份(不包括庫存股 份)數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發 ...